Regeneron drops after skin cancer treatment misses late-stage trial goal
The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS).
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
